fluoxetine has been researched along with Cannabis Abuse in 6 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compared the acute phase (12-week) efficacy of fluoxetine versus placebo for the treatment of the depressive symptoms and the cannabis use of adolescents and young adults with comorbid major depression (MDD) and a cannabis use disorder (CUD) (cannabis dependence or cannabis abuse)." | 5.14 | Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. ( Brown, SJ; Bukstein, OG; Chung, TA; Clark, DB; Cornelius, JR; Daley, DC; Douaihy, AB; Wood, DS, 2010) |
| "The most common withdrawal symptoms among those with cannabis dependence were craving (82%), irritability (76%), restlessness (58%), anxiety (55%), and depression (52%)." | 1.35 | Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. ( Chung, T; Clark, DB; Cornelius, JR; Martin, C; Wood, DS, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cornelius, JR | 4 |
| Aizenstein, HJ | 1 |
| Hariri, AR | 1 |
| Bukstein, OG | 2 |
| Douaihy, AB | 1 |
| Clark, DB | 3 |
| Chung, TA | 1 |
| Daley, DC | 1 |
| Wood, DS | 2 |
| Brown, SJ | 1 |
| Hirschtritt, ME | 1 |
| Pagano, ME | 1 |
| Christian, KM | 1 |
| McNamara, NK | 1 |
| Stansbrey, RJ | 1 |
| Lingler, J | 1 |
| Faber, JE | 1 |
| Demeter, CA | 1 |
| Bedoya, D | 1 |
| Findling, RL | 1 |
| Kaplan, GB | 1 |
| McRoberts, RL | 1 |
| Smokler, HJ | 1 |
| Birmaher, B | 1 |
| Salloum, IM | 1 |
| Brown, SA | 1 |
| Chung, T | 1 |
| Martin, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluoxetine for Major Depressive Disorder/Cannabis Disorder in Young People[NCT00149643] | Phase 2 | 70 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number days out of the last seven days that cannabis was used. (NCT00149643)
Timeframe: 12 Weeks
| Intervention | Days of cannabis use per week (Mean) |
|---|---|
| Fluoxetine | 3.88 |
| Placebo | 3.1 |
Average of Beck Depression Inventory (BDI) Scores measured at Weeks 1-4, 6, 8, 10 and 12. The BDI is a subject reported measure that has a minimim score of 0 and a maximum score of 63. A better outcome would consist of values near the minimum end of the scale (0) and a worse outcome would consist of values near the maximum end of the scare (63). Each DSM-IV criteron asses a different depressive symptom. (NCT00149643)
Timeframe: 12 Weeks
| Intervention | BDI Total (Mean) |
|---|---|
| Fluoxetine | 7.79 |
| Placebo | 7.31 |
Criterion used in this study was the number of DSM-IV cannabis use disorder symptoms (criteria) that were met. (NCT00149643)
Timeframe: 12 Weeks
| Intervention | Number of DSM-IV criterion (Mean) |
|---|---|
| Fluoxetine | 0.59 |
| Placebo | 0.47 |
1 review available for fluoxetine and Cannabis Abuse
| Article | Year |
|---|---|
Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.
Topics: Adolescent; Alcohol Drinking; Alcoholism; Antidepressive Agents, Second-Generation; Combined Modalit | 2005 |
2 trials available for fluoxetine and Cannabis Abuse
| Article | Year |
|---|---|
Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined | 2010 |
Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders.
Topics: Adolescent; Alcoholism; Antidepressive Agents, Second-Generation; Child; Chronic Disease; Depressive | 2012 |
3 other studies available for fluoxetine and Cannabis Abuse
| Article | Year |
|---|---|
Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression.
Topics: Amygdala; Antidepressive Agents, Second-Generation; Cannabis; Comorbidity; Depressive Disorder; Diag | 2010 |
Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Baclofen; Bipolar Disord | 2004 |
Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence.
Topics: Adolescent; Cannabinoids; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Diagnosti | 2008 |